Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01508910
Other study ID # 901001
Secondary ID RENEW Study
Status Completed
Phase Phase 3
First received
Last updated
Start date April 2012
Est. completion date November 2015

Study information

Verified date November 2018
Source Caladrius Biosciences, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to assess the safety and efficacy of targeted intramyocardial delivery of Auto-CD34+ cells for increasing exercise time and amelioration of anginal symptoms in subjects with refractory angina and chronic myocardial ischemia.


Recruitment information / eligibility

Status Completed
Enrollment 291
Est. completion date November 2015
Est. primary completion date November 2015
Accepts healthy volunteers No
Gender All
Age group 21 Years to 80 Years
Eligibility Main Inclusion Criteria:

- Male or female participants who are 21 to 80 years of age at the time of signing the informed consent.

- Participants with Canadian Cardiovascular Society (CCS) class III or IV chronic refractory angina.

- Participants without control of their angina symptoms in spite of maximal tolerated doses of anti-angina drugs. Participants must be on optimal therapy for their angina and must have been on a stable anti-anginal medication regimen for at least 4 weeks before signing the informed consent form.

- Participants with obstructive coronary disease unsuitable for conventional revascularization due to unsuitable anatomy or comorbidity as determined at the site and confirmed by an independent adjudication committee.

- Participants must have evidence of inducible myocardial ischemia.

- Participants must experience angina episodes.

- Participants must be able to complete 2 exercise tolerance tests on the treadmill within 3 weeks of randomization.

- If female of childbearing potential, subject must not be pregnant and agree to employ adequate birth control measures for the duration of the study.

Main Exclusion Criteria:

- Cardiovascular hospitalization within 60 days prior to potential study enrollment. Participant has had a successful or partially successful coronary artery bypass graft (CABG) within 6 months or PCTA within 60 days of potential study enrollment.

- Participant has had a placement of a bi-ventricular pacemaker for cardiac resynchronization therapy (CRT) for heart failure within 180 days of potential study enrollment.

- Participant has documented stroke or transient ischemic attacks (TIAs) within 60 days of potential study enrollment.

- Participant has a history of moderate to severe aortic stenosis; or severe aortic insufficiency; or severe mitral stenosis; or severe mitral insufficiency.

- Participant has a prosthetic aortic valve or a mechanical mitral valve replacement.

- Participant has severe co-morbidity associated with a reduction in life expectancy to less than 3 years as a result of chronic medical illnesses.

- Participants with cancer are excluded with the following exceptions:

- Subjects with in-situ non-melanoma skin cancer or in-situ cervical cancer are not excluded.

- Participants that have been cancer free for >= 5 years as determined by their oncologist are not excluded. Subjects with a prior history of stem cell transplant for cancer are excluded no matter how long they have been cancer-free.

- Participants with a history of leukemia or other bone marrow disease.

- Participant has sickle cell disease or sickle cell trait.

- Participants with proliferative retinopathy.

- Participants with Hb A1c > 9%.

- Participant has platelet counts >10% above the upper limit of normal (ULN) or platelet counts < 70,000.

- Participant has a hematocrit < 30% prior to potential study enrollment.

- Participant has a serum creatinine > 2.5 mg/dL prior to potential study enrollment.

- Participant tests positive for HIV, hepatitis B, or hepatitis C, or is on chronic immunosuppressive medications, or has had a previous stem cell transplant.

- Participant has a known contraindication to Neupogen (filgrastim) or G-CSF.

- Participant was previously enrolled in an active treatment group of cell therapy trials for cardiovascular disease including any phase of CD34+ stem cell trials.

- Left ventricular (LV) thickness of < 7 mm in the target areas of injection as measured by during a 2-D echocardiogram (ECHO).

- Atrial fibrillation, atrial flutter, or other uncontrolled arrhythmias that would prohibit accurate electromechanical mapping and NOGA-guided intramyocardial injection.

- Bleeding diathesis with an INR > 1.8 when not receiving anti-thrombotic therapy.

- Hepatic dysfunction as evidenced by elevated AST or ALT levels > 2.5 x ULN.

- Any previous transplant requiring immunosuppression.

- Disease state requiring chronic immunosuppression.

Study Design


Intervention

Biological:
Auto-CD34+ cells
10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells
Placebo: Diluent used to suspend Auto-CD34+ cells
10 intramyocardial injections of 0.2 mL per injection site of placebo
Other:
Standard of care
Standard of care for refractory angina

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Caladrius Biosciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Total Exercise Time on Exercise Tolerance Test (ETT) Using the Modified Bruce Protocol Baseline (BL) is the average of the two total exercise times measured during the screening period. Baseline and 12 month visit
Secondary Angina Frequency (Episodes Per Week) at the 12 Month Follow-up Visit Participants self-reported angina episodes utilizing an electronic diary for 4 weeks at baseline (screening period) and in the 4 weeks before the 3, 6 and 12 month follow-up visits. Baseline and 12 month visit
Secondary Change From Baseline in Total Exercise Time on Exercise Tolerance Test (ETT) at the 6 Month Follow-up Visit Baseline (BL) is the average of the two total exercise times measured during the screening period. Baseline and 6 month visit
Secondary Angina Frequency (Episodes Per Week) at the 6 Month Follow-up Visit 6 month visit
Secondary Percentage of Participants With Incidences of MACE From Randomization Until the End of the 24 Month Follow-up Period Major adverse cardiac events (MACE) defined as death, cardiac hospitalization, non-fatal myocardial infarction and stroke, as adjudicated by an independent clinical endpoint classification (CEC) committee.
The category Total MACE includes death, cardiovascular hospitalization, myocardial infarction or stroke.
From randomization until the end of the 24 month follow-up period
Secondary Percentage of Participants With at Least One Serious Adverse Event (SAE) From Randomization Until the End of the 24 Month Follow-up Period From randomization until the end of the 24 month follow-up period
See also
  Status Clinical Trial Phase
Withdrawn NCT03438500 - Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve N/A
Recruiting NCT01711099 - Efficacy of Extracorporeal Shockwave Myocardial Revascularization N/A
Active, not recruiting NCT03039751 - Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris Phase 2
Suspended NCT01567592 - Extracorporeal Shockwave Therapy for the Treatment of Chronic Angina Pectoris Phase 1
Recruiting NCT05711849 - Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina Phase 2
Active, not recruiting NCT01241968 - Extracorporeal Shock Wave Therapy for the Treatment of Ischemic Heart Disease Phase 2
Recruiting NCT02499250 - Effect of Daily Remote Ischemic Conditioning on the Life Quality of Refractory Angina Pectoris Patients N/A
Completed NCT01219218 - Extracorporeal Shockwave Therapy for the Treatment of Advanced Angina Pectoris Phase 1
Active, not recruiting NCT01567644 - Extracorporeal Shockwave Therapy for the Treatment of Refractory Chronic Angina Pectoris Phase 1
Completed NCT00662727 - Extracorporeal Shockwave Therapy for the Treatment of Refractory Angina Pectoris Phase 2
Completed NCT04121845 - CoROnary SinuS Reducer implantatiOn for ischemiA reDuction N/A
Active, not recruiting NCT05174572 - IMR Evaluation in Patients With Coronary Sinus Reducer Implantation (INROAD Study) N/A
Recruiting NCT04915157 - Efficacy of Spinal Cord Stimulation in Patients With Refractory Angina Pectoris N/A